BASF Shores Up Specialty Amines Supply
BASF is expanding its Verbund site in Ludwigshafen to include production capacity for about 20 specialty amines.
BASF will expand its production capacity at its Verbund site in Ludwigshafen, Germany. The expansion will include the production capacity for about 20 specialty amines by early 2017 with an investment of an undisclosed double-digit million-euro amount, according to the press release.
BASF currently makes approximately 200 different amines including alkyl-, alkanol-, and alkoxyalkylamines, heterocyclic and aromatic, and specialty amines. Last Spring, the company announced the expanded capacity for amines at Verbund and in Nanjing, China, with startup plans expected in 2015.
The investment aims to meet growing demand in Europe, said Stefan Blank, president of BASF Intermediates division, in a press release. In January 2015, BASF announced that it planned to invest up to $65 million USD to expand some of its facilities, including the Ludwigshafen, Germany site, for its Polyvinyl pyrrolidone capabilities.
Source: BASF
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
